Small Cell Lung Cancer
380
57
74
144
Key Insights
Highlights
Success Rate
73% trial completion
Published Results
75 trials with published results (20%)
Research Maturity
144 completed trials (38% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
13.7%
52 terminated out of 380 trials
73.5%
-13.0% vs benchmark
11%
41 trials in Phase 3/4
52%
75 of 144 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 144 completed trials
Clinical Trials (380)
PF-07104091 as a Single Agent and in Combination Therapy
A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
DESTINY-PANTUMOUR04
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer
Study of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
SMARCA4/2 Inhibitor for POU2F3-Positive SCLC
Comprehensive Oncogenomic Mapping and Exploration in Thoracic and Head & Neck Oncology
A Study of DXC014 in Patients With Advanced Solid Tumors.
Nab-Paclitaxel Combined With Local Therapy in Relapsed SCLC
Tarlatamab for SCLC Brain Metastases
Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)